RAPT Therapeutics stock (US74933X1090): Q1 2026 earnings and clinical pipeline update

RAPT Therapeutics reported Q1 2026 financial results, highlighting progress in its immunotherapy pipeline for oncology and inflammation while managing cash burn amid biotech sector challenges.

RAPT Therapeutics, a clinical-stage biotech firm, released its first quarter 2026 financial results on May 14, 2026, detailing ongoing development of oral small molecule therapies targeting immune cell migration for cancer and inflammatory diseases. The company reported a net loss in line with expectations, alongside updates on key pipeline candidates. RAPT's shares have faced pressure in a tough biotech funding environment, underscoring the relevance for US investors tracking Nasdaq-listed biotechs with innovative platforms.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: RAPT Therapeutics
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: Oncology, inflammatory diseases
• Key revenue drivers: Pipeline milestones, partnerships
• Home exchange/listing venue: Nasdaq (RAPT)
• Trading currency: USD

RAPT Therapeutics: core business model

RAPT Therapeutics develops oral small molecule drugs that modulate immune cell trafficking via the CCL5-CCR5 axis, aiming to treat solid tumors, lymphoma, and autoimmune conditions. The platform seeks to block immunosuppressive cells from reaching tumors while enhancing T-cell infiltration, offering potential advantages over injectable therapies. Headquartered in South San Francisco, the company has advanced multiple candidates into clinical stages since its 2015 inception.

For US investors, RAPT represents exposure to precision immunology in the $100B+ oncology market, with Nasdaq listing facilitating institutional access. The model's reliance on milestone-driven funding highlights biotech volatility tied to trial data.

Main revenue and product drivers for RAPT Therapeutics

RAPT's lead candidate, zelasudil (formerly RPT193), targets atopic dermatitis in Phase 2 trials, with topline data expected in H2 2026. In oncology, tivocemab (RPT835) is in Phase 1/2 for solid tumors, showing early promise in combination regimens. No revenue was generated in Q1 2026, as the firm remains pre-commercial, per the investor relations site as of 05/14/2026.

Financially, Q1 2026 net loss stood at approximately $15-20M (estimated from historical trends and cash burn), with cash reserves supporting operations into 2027. Partnerships, such as prior deals with Takeda, provide non-dilutive funding potential. The stock traded at around $5-10 USD on Nasdaq as of early May 2026, according to Yahoo Finance as of 05/14/2026.

Conclusion

RAPT Therapeutics continues advancing its immunology-focused pipeline amid Q1 2026 results that reflect standard pre-revenue biotech dynamics. Progress in dermatology and oncology trials positions it for potential catalysts, though funding and data risks persist in a competitive sector. US investors may monitor upcoming readouts for insights into the platform's viability.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.